ATAI•benzinga•
atai Life Sciences Doses First Patient Dosed In Phase 2 Study Of EMP-01 For Social Anxiety Disorder; Topline Data anticipate In Q1 Of 2026
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 13, 2025 by benzinga